Condition
Bile Acid Synthesis Defect
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Completed2
Suspended1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04306939Suspended
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
NCT01438411Phase 3CompletedPrimary
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
NCT01589523Phase 3CompletedPrimary
GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
Showing all 3 trials